Goldman Sachs initiated coverage of Teva (TEVA) with a Buy rating and $24 price target The firm sees an improving core business, with upside to near-mid-term consensus EBITDA estimates driven by “strong growth” in the branded segment. Goldman’s estimates are 6% above consensus EBITDA estimates in 2027 and it sees the potential for this to expand further on continued execution. Teva’s pipeline optionality represents a “significant valuation lever,” adds the firm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva Pharmaceutical Elects New Board Members at Annual Meeting
- Teva announces early tender results of debt tender offer
- Teva announces results from a study of treatment patterns of tardive dyskinesia
- Kyverna, Rocket, Teva, Fair Isaac, Oklo Trending by Analysts
- Teva Pharmaceutical’s Promising Long-term Outlook: Buy Rating Backed by Strategic Initiatives and FCF Growth Potential